Yüklüyor......

MEK/ERK inhibitors: proof-of-concept studies in lung fibrosis

There is no therapy for chronic fibroproliferative diseases, in spite of the fact that current health statistics suggest that these (which include cardiovascular disease, pulmonary fibrosis, diabetic nephropathy, liver cirrhosis and systemic sclerosis) have been estimated to cause approximately 45%...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yazar: Leask, Andrew
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Springer Netherlands 2011
Konular:
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3271198/
https://ncbi.nlm.nih.gov/pubmed/22131200
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12079-011-0156-9
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!